It’s Official: FDA Approval Does Not Equal CMS Coverage
This article was originally published in RPM Report
Executive Summary
Medicare’s updated coverage determination policy spells out in black-and-white that the payor agency does not feel that the law requires it to pay for FDA-approved products used on-label.
You may also be interested in...
Straight Talk About Cancer Drug Coverage
CMS’ coverage of cancer drugs isn’t as automatic as you think. Here’s how the Medicare agency sees it.
The Gene Therapy Wave Is Here
The long-talked about wave of gene therapy approvals is beginning to reveal itself.
Will The Excise Tax Torpedo The IRA Drug Price Negotiation Program?
A case involving a tax that was an “exceedingly heavy burden” and played into the Supreme Court’s original ruling on the ACA could reemerge once the IRA challenge reaches the high court.